Bruce D. Cheson
Cheson, Bruce D., 1946-....
Cheson, Bruce D.
Cheson, B. D.
VIAF ID: 85858205 (Personal)
Permalink: http://viaf.org/viaf/85858205
Preferred Forms
- 100 0 _ ‡a Bruce D. Cheson
- 200 _ | ‡a Cheson ‡b Bruce D. ‡f 1946-....
- 100 1 _ ‡a Cheson, B. D.
-
-
- 100 1 _ ‡a Cheson, Bruce D.
-
- 100 1 _ ‡a Cheson, Bruce D. ‡d 1946-
- 100 1 0 ‡a Cheson, Bruce D., ‡d 1946-
-
- 100 1 _ ‡a Cheson, Bruce D., ‡d 1946-....
4xx's: Alternate Name Forms (2)
Works
Title | Sources |
---|---|
Basic clin. oncol. (Online) | |
Chronic lymphoid leukemias | |
Hoffman and Abeloff's hematology - oncology review | |
New Chemotherapeutic Agents for Non-Hodgkin’s Lymphomas | |
Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496) | |
The repression-sensitization scale and measures of prejudice | |
Resolution of Lymphoma-associated Open-angle Glaucoma by Rituximab | |
Response criteria for NHL: importance of 'normal' lymph node size and correlations with response rates | |
Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901 | |
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma | |
Resveratrol and cancer prevention. | |
Rethinking clinical response and outcome assessment in a biologic age. | |
Retinoids in cancer therapy | |
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia | |
Revised response criteria for malignant lymphoma | |
Risky management. | |
Rituximab: clinical development and future directions | |
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. | |
The role of body mass index in survival outcome for lymphoma patients: US intergroup experience | |
The role of complement and IgG on zymosan opsonization | |
The role of FDG-PET scans in patients with lymphoma | |
The role of radioimmunotherapy with yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma | |
Safe and effective treatment of aggressive non-hodgkin lymphoma with rituximab and bendamustine in patients with severe liver impairment | |
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. | |
The sarcoid-lymphoma syndrome | |
Sequential doxorubicin and topotecan in relapsed/refractory aggressive non-Hodgkin's lymphoma: results of CALGB 59906 | |
Sequential homoharringtonine and interferon-alpha in the treatment of early chronic phase chronic myelogenous leukemia | |
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism | |
Small molecules, big challenges. | |
Some like it hot! | |
Speaking volumes about volumes | |
Speed bumps on the road to a chemotherapy-free world for lymphoma patients | |
Splenectomy for Immune Thrombocytopenic Purpura | |
Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes | |
State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response". | |
Summer happenings in Hematology 2011. Highlights in Hematological Malignancies form the 2011 American Society Clinical Oncology Annual Meeting and the 16th Congress of the European Hematology Association, and the 11th International Conference on Mal | |
Suramin therapy in AIDS and related disorders. Report of the US Suramin Working Group | |
Syk [sic] of the same old chemotherapy? | |
The systemic administration of intravenous melphalan | |
Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions | |
Targeted treatment and new agents in follicular lymphoma | |
Targeting Biology in Non-Hodgkin Lymphoma | |
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B. | |
Therapy for diffuse large B-cell lymphoma: getting personal | |
Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501) | |
Time to remember to forget dose-intensification in lymphoma | |
Total therapy with tandem transplants for newly diagnosed multiple myeloma | |
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis | |
Trans-retinoic acid and related differentiation agents | |
Trials and tribulations | |
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice | |
Ultrastructural evidence for persistent gold in the bone marrow of a patient with aplastic anemia | |
Urinary cytodiagnosis of renal involvement in disseminated histiocytic lymphoma | |
Urinary cytodiagnostic abnormalities in 50 patients with non-Hodgkin's lymphomas | |
The urinary myeloma cast. Frequency of detection and clinical correlations in 30 patients with multiple myeloma | |
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. | |
Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma | |
Value of open-lung biopsy in 87 immunocompromised patients with pulmonary infiltrates | |
Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial | |
Waiting is the hardest part | |
We need the Annual Oncology Awards | |
What is new in lymphoma? | |
When I came to the National Cancer Institute. | |
Which Hodgkin's patients in the Unites States should be treated with BEACOPP? |